Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Novel antioestrogens without partial agonist activity.

A E Wakeling1, J Bowler

  • 1Imperial Chemical Industries plc, Pharmaceuticals Division, Cheshire, England.

Journal of Steroid Biochemistry
|October 1, 1988
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Metal hypersensitivity in total joint replacement: review of the literature and practical guidelines for evaluating prospective recipients.

Orthopedics·2014
Same author

The reversible cerebral vasoconstriction syndrome in association with venlafaxine and methenamine.

BMJ case reports·2013
Same author

Birth of a biome: insights into the assembly and maintenance of the Australian arid zone biota.

Molecular ecology·2008
Same author

Consensus statement. Workshop on therapeutic resistance in breast cancer: impact of growth factor signalling pathways and implications for future treatment.

Endocrine-related cancer·2005
Same author

Inhibitors of growth factor signalling.

Endocrine-related cancer·2005
Same author

Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells.

Endocrine-related cancer·2004

ICI 164384, a novel 7 alpha-alkyl amide derivative of 17 beta-estradiol, exhibits potent pure antiestrogen properties. It effectively blocks estrogenic actions and inhibits breast cancer cell growth without estrogenic side effects.

Area of Science:

  • Endocrinology
  • Pharmacology
  • Molecular Biology

Background:

  • 17 beta-estradiol derivatives are crucial in hormone research.
  • Understanding estrogenic and antiestrogenic activities is vital for therapeutic development.

Purpose of the Study:

  • To evaluate the estrogenic and antiestrogenic properties of novel 7 alpha-alkyl amide derivatives of 17 beta-estradiol.
  • To characterize the compound ICI 164384 as a potential pure antiestrogen.

Main Methods:

  • In vivo studies in rats and mice to assess uterotrophic and vaginal/hypothalamic-pituitary axis activity.
  • In vitro studies using MCF-7 and ZR-75-1 breast cancer cells to evaluate cell growth inhibition.
  • Competitive binding assays to determine estrogen receptor affinity.

Related Experiment Videos

Main Results:

  • ICI 164384 demonstrated no estrogenic activity in rat and mouse reproductive tissues and the hypothalamic-pituitary axis.
  • ICI 164384 completely antagonized the effects of both endogenous and exogenous estradiol, as well as partial agonist antiestrogens like tamoxifen.
  • ICI 164384 showed higher affinity for the estrogen receptor than tamoxifen and was a more potent inhibitor of breast cancer cell growth, with inhibition reversed by estradiol.

Conclusions:

  • ICI 164384 possesses significant pure antiestrogenic properties.
  • Its potent antiestrogenic activity and efficacy in inhibiting breast cancer cell proliferation suggest therapeutic potential.
  • ICI 164384 meets key criteria defining pure antiestrogens, distinguishing it from partial agonists like tamoxifen.